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Abstract
Background: Patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) are apparently exposed to 
enhanced oxidative stress and to inﬂ  ammation. It was the aim of this study to characterize the state of systemic oxidative 
stress of ESRD patients before and following HD using highly speciﬁ  c biomarkers, F2-isoprostanes and 4-hydroxynonenal 
(HNE). Furthermore the question should be answered, if there are associations between inﬂ  ammation and systemic oxida-
tive stress and/or between systemic oxidative stress and renal anemia, which is more or less typical for HD patients.
Patients and methods: Concentrations of F2-isoprostanes, HNE, C-reactive protein (CRP) as marker of inﬂ  ammation, and 
hemoglobin were measured in serum samples of patients with ESRD before and after HD and of healthy control persons 
for comparison. Total (esteriﬁ  ed plus free) F2-isoprostanes were quantiﬁ  ed by highly sensitive gas chromatography/mass 
spectrometry technique, HNE by thin layer chromatography and HPLC/UV detection, CRP by immunoturbidimetry and 
hemoglobin by clinico-chemical routine assay.
Results: 1. HD patients showed signiﬁ  cantly higher serum concentrations of F2-isoprostanes and HNE than healthy human 
control subjects. 2. Total (esteriﬁ  ed plus free) F2-isoprostane levels before HD were not signiﬁ  cantly different from those after 
HD, whereas HNE levels were signiﬁ  cantly decreased in patients after HD. 3. F2-isoprostane concentrations in HD patients 
correlated with the levels of CRP, whereas HNE concentrations inversely correlated with the content of hemoglobin.
Conclusion: Both, F2-isoprostanes and HNE serum concentrations are useful oxidative stress parameters in ESRD patients 
undergoing HD. Whereas HNE strongly correlates with the severity of renal anemia, leading to left heart insufﬁ  ciency, 
F2-isoprostanes (sum of free plus esteriﬁ  ed) highly correlate with the degree of inﬂ  ammation.
Keywords: F2-isoprostanes, end-stage renal disease (ESRD), hemodialysis patients, C-reactive protein, 4-hydroxynonenal, 
renal anemia
Introduction
Hemodialysis (HD) in end-stage renal disease (ESRD) patients is associated with the development of 
oxidative stress, caused by the impairment of antioxidant defences and the bioincompatibility of the 
dialysis technique contributing to cardiotoxic effects (Canaud et al. 1999).
Reactive oxygen species (ROS) are known to play a role in the pathogenesis and progression of 
chronic renal failure (CRF). Apart from the kidney disease itself and the uremia, numerous other factors 
appear to contribute to oxidative stress (Trachtman et al. 1992), including HD via contact activation 
of neutrophils by the artiﬁ  cial surfaces of the dialysis membrane and the tubing system (Westhuyzen 
et al. 1995).
Increased levels of oxidants (e.g. malonic dialdehyde) and lower levels of antioxidants (glutathione, 
α-tocopherol) in CRF patients play an important role in the development of endothelial dysfunction, ath-
erogenesis and cardiovascular disease (Loughrey et al. 1994; Delmas Beauvieux et al. 1995; 420
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Ceballos-Picot et al. 1996; Cavdar et al. 1997; 
Peuchant et al. 1997; Sommerburg et al. 1998; 
Ludat et al. 2000; Siems et al. 2002a; Siems et al. 
2002b). A more speciﬁ  c biomarker of oxidative 
stress represents HNE, one of the major end prod-
ucts of lipid peroxidation generated mainly from 
arachidonic acid. HNE has cytotoxic and mutagenic 
properties, induces apoptosis, NF-κB activation and 
inhibition of enzyme activities (Esterbauer et al. 
1991; Sommerburg et al. 1993; Grune et al. 1994; 
Siems et al. 1996; Sommerburg et al. 1998; Uchida 
et al. 1999; Ruef et al. 2001).
Previously, ﬁ  rst reports on F2-isoprostanes as 
indicators of lipid peroxidation in renal diseases 
were published (Spittle et al. 2001; Handelman 
et al. 2001; Ikizler et al. 2002; Lim et al. 2002; 
Danielski et al. 2003; Ferraro et al. 2003; Kim 
et al. 2004; Wiswedel et al. 2005). F2-Isoprostanes 
have been established as chemically stable, highly 
speciﬁ  c and reliable biomarkers of in vivo oxida-
tive stress, which can be very sensitively measured 
by gas chromatography/mass spectrometry 
(Morrow et al. 2002). Measurements in dialysis 
patients before dialysis showed higher plasma 
levels of F2-isoprostanes than in control subjects 
(Spittle et al. 2001; Handelman et al. 2001). But 
the data are not unique: in contrast to the data of 
Spittle et al. (2001) and of Handelman et al. 
(2001), Dogra et al. (2001) did not ﬁ  nd an increase 
in plasma and urinary F2-isoprostanes in patients 
with nephrotic syndrome.
Both arachidonic acid oxidation products, 
F2-isoprostanes and HNE, are known to be involved 
in atherogenesis and myocardial injury (Blasig 
et al. 1995; Ruef et al. 2001; Morrow et al. 2002), 
which is the most critical point of life quality and 
mortality in CRF (Foley et al. 1995; Silverberg 
et al. 2000). There are also strong interactions 
between both types of cardiovascular risk factors, 
e.g. HNE induces the formation of 8-iso-PGF2α in 
vascular smooth muscle cells (Ruef et al. 2001).
HD patients are not only exposed to enhanced 
oxidative stress, but also to inﬂ  ammation (Spittle 
et al. 2001). Cardiovascular mortality remains high 
in ESRD patients, particularly in the group with 
evidence for inflammation (Yeun and Kaysen 
2000). Inﬂ  ammation may enhance oxidative stress 
through increased free radical generation via acti-
vation of NADPH oxidase and may directly 
modify proatherogenic factors.
The aim of this paper is 1. to determine 
F2-isoprostanes and HNE in the serum of ESRD 
patients before and following HD and for 
comparison in healthy control persons and 2. to 
examine if the markers of oxidative stress are 
correlated to the degree of inﬂ  ammation and/or to 
the degree of renal anemia.
Patients and Methods
Patients
Patients and probands were required to provide 
written informed consent before the start of the 
evaluation. The place of dialysis was at the dialy-
sis centre of Scorrano, Italy. Inclusion criteria 
of patients were as follows: presence of renal 
anemia (hemoglobin concentration11 g/dl, 
time on dialysis 6 months, treatment in the 
center 3 months, normal values of GOT, GPT, 
LDH and γ-GT. Among the egligible patients the 
anamnesis about their life style required to exclude 
12 persons because of smoking. Further criteria of 
exclusion were: patients taking antioxidants, 
patients with acute infection, with considerable 
iron overload, with an acute phase of rheumato-
logical disorders and with neoplasiae. Furthermore, 
HD patients without well-functioning vascular 
excess and patients treated by vitamin E-bounded 
membranes were excluded. Only one patient was 
excluded at the end of the dialysis study because 
of wrong sampling. 14 patients came with hyper-
tension. We aimed a strict control of hypertension 
with a target blood pressure 130/80 mm Hg 
(β-receptor blocker, ACE-I inhibitors, angiotensin 
II receptor blocker). For the investigated patients 
the “dry” weight was deﬁ  ned by impedenziometry 
and the “dry” weight was reached at the end of the 
HD session. 12 patients had intima media thickness 
and ﬁ  ve of them had also documented one or more 
carotid plaques measured by B-mode ultrasonog-
raphy. For 11 patients a left ventricular hypertrophy 
was documented, 16 patients were treated with 
erythropoietin. All patients were treated three 
times/week. High ﬂ  ux dialysis ﬁ  lters consisting of 
polysulphone/polyacrylonitrile were used. The 
evaluation was done at the midweek dialysis ses-
sion. The participants of the control group were 
healthy persons from the dialysis centers in Scor-
rano and Berlin (nurses, doctors, technicians etc.). 
F2-isoprostane concentrations (8-iso-PGF2α and 
9α,11α-PGF2α) and HNE in correlation to CRP 
and hemoglobin content were analysed in 14 non-
diabetic HD patients with chronic renal failure 421
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(6 male, 8 female, middle age 59 ± 14 years). 
F2-isoprostanes before and following hemodialysis 
were compared in 19 non-diabetic ESRD patients (5 
additional patients: 2 male, 3 female, from the same 
age group). There were also control groups for 
analysis of F2-isoprostanes with 65 (30 male, 
35 female, middle age 55 ± 15 years) and for 
analysis of HNE with 131 healthy probands 
(77 male and 54 female, middle age 60 ± 10 years).
Sample extraction, hydrolysis 
and puriﬁ  cation of F2-isoprostanes
The determination of the concentrations of 
F2-isoprostanes (sum of esteriﬁ  ed and non-esteriﬁ  ed 
isomers) was carried out as described previously 
(Wiswedel et al. 2004) with some modiﬁ  cations. 
To hydrolyze esteriﬁ  ed lipids, the serum samples 
(1.0 mL) were treated with 320 μL of KOH (1 mol/L) 
at 40 °C for 30 min. Thereafter, the samples were 
neutralized by addition of 3 mL HCl (0.1 mol/L), 
and the pH was adjusted to 2 with HCl (1 mol/L). 
9α,11α-PGF2α-d4 (1 ng in 20 μL ethanol) was added 
as internal standard. The samples were centrifuged 
at 5,000 × g for 15 min, and the supernatant 
was applied onto a C18-cartridge, pre-washed with 
5 mL of methanol and 5 mL of water. The cartridge 
was then washed with 10 mL HCl (0.1 mol/L) and 
10 mL of acetonitrile/water (15/85, v/v). Isoprostanes 
were eluted from the column with 5 mL of n-hexane/
ethyl acetate/2-propanol (30/65/5, v/v/v). The 
prostanoid extract was applied then onto a NH2-
cartridge, pre-washed with n-hexane (10 mL). The 
column was successively washed with 10 mL of 
n-hexane/ethyl acetate (30/70, v/v), acetonitrile/
water (90/10, v/v) and acetonitrile. Finally, 
F2-isoprostanes were eluted with 5 mL of ethyl 
acetate/methanol/acetic acid (10/85/5, v/v/v).
Derivatization and GC-MS/negative 
ion chemical ionization analysis
The extracts from the NH2-chromatography step 
were evaporated to dryness under a stream of argon 
at 45 °C. The residues were reconstituted with 40 μL 
of pentaﬂ  uorobenzyl-bromide (10% in acetonitrile) 
and 20 μL of N,N-diisopropylethylamine (10% in 
acetonitrile) and incubated at 45 °C for 30 min. 
Thereafter, 50 μL of bis-(trimethylsilyl) triﬂ  uoro-
acetamide (BSTFA) and 5 μL of N,N-diisopropyl-
ethylamine were added to the dried sample. The 
samples were kept at 45 °C for 45 min, the solvents 
were removed, and the samples were reconstituted 
in 40 μL isooctane containing 0.1% BSTFA. 
F2-isoprostanes were separated by GC/MS using the 
following temperature program: initial temperature 
of 175 °C for 2 min; with a rate of 30 °C/min to a 
ﬁ  nal temperature of 270 °C maintained for 20 min; 
total run time: 25.2 min. Quantitative analysis 
was performed with ammonia as reagent gas 
using selected ion monitoring (SIM) of the carbox-
ylate anion [M-181]
– at m/z 569 and 573 for 
F2-isoprostanes and 9α,11α-PGF2α-d4, respectively. 
The m/z 569 ion current chromatogram showed the 
occurrence of two major peaks in serum samples, 
peak I co-eluting with authentic 8-iso-PGF2α 
and peak II co-eluting with authentic 9α,11α-PGF2α. 
Peak I is expected to contain exclusively F2-
isoprostanes, whereas peak II may contain both, 
mainly F2-isoprostanes, but additionally cyclooxy-
genase-derived PGF2α (Wiswedel et al. 2004).
The response factors for the isoprostane iso-
mers were 1.00 and 0.55 for 9α,11α- and 8-iso-
PGF2α, respectively (means of three separate 
determinations).
F2-isoprostane analyses were performed in 
triplicate throughout for each plasma sample.
Determination of CRP and hemoglobin
CRP was measured by immunoturbidimetry (Grüt-
zmeier and von Schenck, 1989), and hemoglobin 
with spectrophotometric methods within the clini-
cal laboratory routine parameters. CRP and hemo-
globin concentrations were 16.6 ± 3.8 mg/L serum 
resp. 9.75 ± 0.64 g/dl (mean ± SEM n = 14) for HD 
patients and 3.3 ± 0.1 resp. 15.1 ± 0.4 (mean ± SEM, 
n = 131; p  0.05 resp. p  0.01; patients versus 
controls) for healthy control persons.
4-Hydroxynonenal (HNE) analysis
The measurement of HNE includes the modiﬁ  ca-
tion of this aldehyde with dinitrophenylhydrazine, 
the thin layer chromatographic analysis of the 
dinitrophenylhydrazones in three groups, and 
ﬁ  nally the isocratic analysis of the dinitrophenyl-
hydrazine derivatives of the 4-hydroxyalkenales 
(Esterbauer et al. 1982; Grune et al. 1994; 
Sommerburg et al. 1993). During the HPLC-
analysis a mixture of methanol and water (4:1, v:v) 
was used as an eluent. The detection-wavelength 
was set to 378 nm. The HNE-standard was pro-
duced from the diacetale which was stored in a 
chloroform solution at –20 °C.422
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Statistical analyses
All data are presented as mean ± SEM. Comparisons 
between independent groups (patients versus controls) 
have been performed with the two-sample t test, com-
parisons between dependent groups (before and after 
dialysis) with the t test for paired data. Correlations 
between variables have been investigated with linear 
regression and Pearson’s correlation coefﬁ  cient. All 
tests have been carried out two-sided and P values 
below 0.05 were considered to be signiﬁ  cant.
Results
Data concerning serum concentrations of F2-
isoprostanes as biomarkers of the oxidative status 
of HD patients and normal control persons are 
shown in Figure 1. It can be seen that HD patients 
(4.69 ± 0.81 and 3.56 ± 0.42 pmol/mL) exhibited 
4.2-fold (8-iso-PGF2α) and 2.8-fold (9α,11α-PGF2α) 
higher F2-isoprostane serum levels than healthy 
controls (1.12 ± 0.05 and 1.28 ± 0.11 pmol/mL). 
Furthermore, F2-isoprostane concentrations did not 
signiﬁ  cantly change in patients before and following 
hemodialysis, as was shown in Figure 2a and 2b.
For 8-iso-PGF2α and 9α,11α-PGF2α, correla-
tions with a representative parameter of inﬂ  amma-
tion (CRP) and with a representative parameter 
of the degree of renal anemia (hemoglobin con-
centration) were examined. Figure 3 shows the 
correlations of F2-isoprostane concentrations 
[9α,11α-PGF2α (Fig. 3a) and 8-iso-PGF2α (Fig. 3b)] 
and CRP as parameter for inﬂ  ammatory processes 
in the patients. We demonstrated a positive 
correlation of total (esteriﬁ  ed plus free) F2-isopros-
tane isomers with the degree of inﬂ  ammation, 
whereas no correlation between F2-isoprostanes 
and the degree of renal anemia (hemoglobin 
content) was found (not documented here).
In contrast, HNE, formed as one of the main 
degradation products of arachidonic acid, which is 
signiﬁ  cantly increased in serum samples of ESRD 
patients (Fig. 4a), changed in dependence on hemo-
globin concentrations, i.e. the HNE levels were 
higher with decreasing hemoglobin. It showed, 
therefore, an inverse relationship (signiﬁ  cant nega-
tive correlation) with the degree of renal anemia 
(Fig. 4b). However, no significant correlation 
between the levels of HNE and the C-reactive protein 
(degree of inflammation) was observed (not 
shown).
Discussion
Chronic inﬂ  ammation in HD patients
Many of ESRD and HD patients are in the state 
of chronic inﬂ  ammation. The reason why renal 
failure is a source of inﬂ  ammation has not been 
fully elucidated. A multifactorial origin of inﬂ  am-
mation may be taken in consideration (Stenvinkel 
and Alvestrand, 2002). These include renal 
insufﬁ  ciency (leading in the end stage to uremia) 
and its complications; as already established 
atherosclerosis, diabetes, hypertension; conse-
quences of renal replacement treatment; back-
leakage of endotoxins from contaminated 
dialysate and frequent infections (Tsirpanlis, 
2005). Less biocompatible HD methods may 
contribute to the enhanced stimulation of neutro-
philes and monocytes (through dialysis mem-
brane interaction), the induction of cytokines, as 
IL-1, IL-6, TNFα and the increase of CRP 
Figure 1. F2-Isoprostane concentrations (8-iso-PGF2α and 9α,11α-PGF2α) in serum samples of patients (n = 19) and control persons (n = 65)
Mean values ± SEM; two-sample t test; p  0.001 versus control.
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Figure 2. F2-Isoprostane concentrations [8-iso-PGF2α (a) and 9α,11α-PGF2α (b)] in serum samples of patients before and after hemodialysis 
(n = 19). The differences are not signiﬁ  cant (t test for paired data).
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(Morena et al. 2005). Even at initial stages of 
chronic renal failure, the CRP level is elevated 
(Tsirpanlis, 2005). CRP could be a sensitive risk 
index of the overall morbidity and mortality in 
CRF patients. As an acute phase protein with high 
sensitivity and low speciﬁ  city, CRP is mainly 
synthesized in the liver and may be regulated 
largely by circulating levels of IL-6 (Thaunat 
et al. 2005; Vollenbroeker et al. 2005).
CRP has many features that may contribute to 
an inﬂ  ammatory process: it binds to damaged 
cells and activates the complement system. It 
binds to atherogenic lipoproteins and induces 
aggregation of LDL and VLDL in vitro; and 
stimulates thrombus formation (Galle et al. 2003). 
Bergstrom et al. (2000) and Galle et al. (2003) 
reported that CRP is 5-10-fold higher in HD 
patients than in healthy controls (16.3 vs. 
1.8 mg/L), which is associated with an increased 
cardiovascular risk. In the group of patients which 
we investigated the values were 16.6 vs. 3.3 mg/L, 
i.e. quite similar.
a
b424
Wiswedel et al
Biomarker Insights 2008:3 
Inﬂ  ammation may be mainly 
responsible for oxidative stress
Inﬂ  ammation is discussed as a well-documented 
factor inﬂ  uencing the development of oxidative 
stress in dialysis patients (Wratten et al. 2002). 
The way by which inﬂ  ammation can contribute 
to oxidative stress in chronic renal failure is via 
activation of NADPH oxidase by interleukins 
and anaphylatoxins produced during HD ses-
sions and/or myeoloperoxidase (Morena et al. 
2005). Further sources of ROS are the 
mitochondrial respiratory chain, lipoxygenases, 
cyclooxygenases, xanthin oxidase, and NO 
synthase.
Both ROS and their secondary products are 
involved in the pathophysiological processes in 
ESRD. Oxidative stress, resulting from imbalance 
between oxidant production and antioxidative 
defence mechanisms, has been documented in 
ESRD patients using lipid, protein, nucleic acid 
and carbohydrate oxidative markers (Paleschi et al. 
2007; Rutkowski et al. 2007; Coskun et al. 2007; 
Piroddi et al. 2007; Pai et al. 2007).
A highly signiﬁ  cant positive correlation was 
observed between logCRP and reactive oxygen 
metabolites in HD patients by Samouilidou 
et al. 2007. F2-isoprostanes, associated with the 
inﬂ  ammation process in patients on HD, positively 
correlated with CRP (Handelman et al. 2001; 
Ikizler et al. 2002) as also described in this paper. 
HNE, however, as readily diffusible molecule upon 
dialysis doesn’t follow the increase of CRP in 
chronic renal failure (Siems et al. 2002b and this 
study). Interestingly, an inverse correlation between 
HNE and hemoglobin serum concentrations could 
be demonstrated and therefore a role of HNE as 
predictor of hemolytic anemia was suggested.
Esteriﬁ  ed F2-isoprostanes 
may be not only reliable biomarkers 
of oxidative stress, but also mediators 
of inﬂ  ammation
Measurement of F2-isoprostanes has advantages over 
other quantitative markers of oxidative stress: they 
are chemically stable, specific products of lipid 
Figure 3. Correlation between levels of F2-isoprostanes [8-iso-PGF2α (a) and 9a,11a-PGF2α (b)] and C-reactive protein; n = 14 patients. 
Correlations have been investigated with linear regression analysis.
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peroxidation, they are formed in vivo and are present 
in all normal tissues and biological ﬂ  uids (Montuschi 
et al. 2004). GC-MS is the reference analytical 
method for isoprostane measurement in biological 
ﬂ  uids and tissues. F2-isoprostanes are widely accepted 
to correlate with the cardiovascular risk in human 
beings (Ikizler et al. 2002). This is an additional argu-
ment for the use of F2-isoprostanes in ESRD, which 
is closely connected with cardiac insufﬁ  ciency.
F2-isoprostanes have been found to exert potent 
biological actions and therefore may participate as 
pathophysiological mediators of disease (Montuschi 
et al. 2004). In patients with lung diseases, 8-iso-
PGF2α concentrations in exhaled breath condensate 
reflect the degree of airway inflammation 
(Montuschi et al. 2000) with high levels reported 
in patients with chronic obstructive pulmonary 
disease and in smokers. 8-iso-PGF2α is not only 
known as a pulmonary, but also as a potent renal 
vasoconstrictor. In the rat, F2-isoprostanes reduce 
glomerular ﬁ  ltration rate and renal blood ﬂ  ow by 
40%–45% in the low nanomolar range (Takahashi 
et al. 1992). F2-isoprostanes have important in 
vitro activities that could be relevant to the 
pathophysiology of atherosclerosis. They promote 
platelet activation (Patrono and Fitzgerald, 1997) 
and induce mitogenesis in vascular smooth muscle 
cells (Fukunaga et al. 1993). Moreover, F2-
isoprostane formation is increased during LDL 
oxidation in vitro and F2-isoprostanes are major 
contributors to the proadhesive effect induced by 
minimally oxidatively modiﬁ  ed LDL on neutrophils 
(Fontana et al. 2002). F2-isoprostanes exert their 
biological effects by receptor-mediated interactions 
(acting as full or partial agonists at thromboxane 
receptors) and also by receptor-independent 
mechanisms (Montuschi et al. 2004).
F2-isoprostane serum levels of HD patients in 
this study were significantly increased versus 
healthy control persons. This is in agreement with 
other reports (Walter et al. 2000; Handelman et al. 
2001; Lim et al. 2002). But, there were no signiﬁ  -
cant differences of F2-isoprostane levels before and 
after HD, as was also found by Handelman et al. 
(2001), and in contrast to Kim et al. (2004), who 
observed 4-fold higher levels post hemodialysis.
Both human and experimental studies have 
indicated associations of F2-isoprostanes and severe 
inﬂ  ammatory conditions, diabetes and atherosclerosis. 
Recently it was shown that intravenous administration 
Figure 4a. Serum concentrations of 4-hydroxynonenal in patients with chronic renal failure before and after hemodialysis (n = 14) compared 
to control persons (n = 131). Mean ± SEM, two-sample t test for comparison between patients and controls (p  0.001; before HD vs. con-
trol and p = 0.002; after HD vs. control) and t test for paired data for comparison between patients before and after dialysis (p  0.001).
0
50
100
150
200
250
300
350
H
N
E
 
(
n
m
o
l
/
L
)
controls
patients before HD
patients after HD426
Wiswedel et al
Biomarker Insights 2008:3 
of 8-iso-PGF2α induced cyclooxygenase-mediated 
prostaglandin (PGF2α) formation and activation of 
inﬂ  ammatory responses (Basu, 2004). In another 
recent study, 8-iso-PGF2α induced IL-8 expression in 
human macrophages, a chemokine involved in inﬂ  am-
mation and atherogenesis through mitogen-activated 
protein kinases (Scholz et al. 2003). These studies 
emphasize that F2-isoprostranes might be mediators 
of inﬂ  ammation involving cyclooxygenases and/or 
cytokines and promote a possible link between oxida-
tive stress and inﬂ  ammation.
Increased concentrations of F2-isoprostanes are 
related with high concentrations of CRP. As in our 
measurements also in those of Spittle et al. (2001) 
and Handelman et  al. (2001) was found 
that F2-isoprostanes correlate to the concentration 
of C-reactive protein as one of the most important 
factors in predicting cardiovascular mortality, 
which is by far the main cause of mortality in 
ESRD patients with cardio-renal anemia syndrome 
(Silverberg et al. 2003; 2004a, 2004b).
Conclusions and outlook
In this study it was shown that ESRD patients under-
going hemodialysis are exposed to enhanced oxida-
tive stress and to inﬂ  ammation. The main limitations 
of this study were the relatively small number of 
patients and the obviously incomplete consideration 
of all parameters inﬂ  uencing inﬂ  ammation and/or 
oxidative stress (e.g. lipid metabolism, blood 
pressure, cardiovascular disorders).
Biomarkers of oxidative stress, F2-isoprostanes 
and HNE, are signiﬁ  cantly increased in the serum 
of patients and are highly correlated either to the 
degree of inﬂ  ammation or renal anemia as well. 
Inflammation and oxidative stress may act 
synergistically to increase cardiovascular 
morbidity and mortality risk in the patients. The 
correction of anemia (e.g. by erythropoietin) reduces 
the oxidative stress to some extent, and also the 
cardiovascular risk. The prevention of oxidative 
stress in HD might, however, also focus on improving 
the hemocompatibility of the dialysis system, the 
supplementation of antioxidants and the modulation 
of NADPH oxidase by pharmacological approaches. 
In order to prove the effectiveness of therapeutic 
interventions, further efforts are obligatory. These 
include the enlargement and proper selection of 
suitable biomarkers that can be related to the 
pathogenesis and the development of the disease. 
Concerning F2-isoprostanes and partially HNE, most 
of the strict criteria for validation of the use of a 
biomarker in vivo (Biomarker Deﬁ  nition Working 
Group, 2001) are appropriate, but they only do reﬂ  ect 
the ROS-mediated oxidation of arachidonic acid. 
Further limitations are 1. that the analysis of the used 
Figure 4b. Correlation between HNE concentrations and hemoglobin content (n = 14 patients).
Correlations have been investigated with linear regression analysis.
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biomarkers (in particular F2-isoprostanes) is 
labor-intensive and requires expensive equipment 
and 2. an increase in F2-isoprostanes locally in 
tissues is not detected by measuring systemic oxidant 
stress. For HD patients it should be taken into 
account that small molecules, as HNE and possibly 
free F2-isoprostanes (but not esteriﬁ  ed) are washed 
out during dialysis. It would be necessary, therefore, 
to follow up the serum or plasma concentrations of 
esterified F2-isoprostanes and those of other 
biomarkers, which have to be defined, very 
thoroughly in longitudinal studies.
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